These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 27016922)

  • 1. Sclerostin Inhibition in the Management of Osteoporosis.
    Appelman-Dijkstra NM; Papapoulos SE
    Calcif Tissue Int; 2016 Apr; 98(4):370-80. PubMed ID: 27016922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
    Clarke BL
    Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-sclerostin - is there an indication?
    Larsson S
    Injury; 2016 Jan; 47 Suppl 1():S31-5. PubMed ID: 26768288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological agents in management of osteoporosis.
    Tella SH; Gallagher JC
    Eur J Clin Pharmacol; 2014 Nov; 70(11):1291-301. PubMed ID: 25204309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future directions for new medical entities in osteoporosis.
    Ferrari S
    Best Pract Res Clin Endocrinol Metab; 2014 Dec; 28(6):859-70. PubMed ID: 25432357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Romosozumab: from basic to clinical aspects.
    Minisola S
    Expert Opin Biol Ther; 2014 Sep; 14(9):1225-8. PubMed ID: 24835636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders.
    Marini F; Giusti F; Palmini G; Brandi ML
    Osteoporos Int; 2023 Feb; 34(2):213-238. PubMed ID: 35982318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: A critical assessment of the mechanism of action.
    Bhattacharyya S; Pal S; Chattopadhyay N
    Eur J Pharmacol; 2018 May; 826():39-47. PubMed ID: 29476877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab.
    Reid IR
    BioDrugs; 2017 Aug; 31(4):289-297. PubMed ID: 28547661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerostin and skeletal health.
    Sharifi M; Ereifej L; Lewiecki EM
    Rev Endocr Metab Disord; 2015 Jun; 16(2):149-56. PubMed ID: 25669441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.
    Recker RR; Benson CT; Matsumoto T; Bolognese MA; Robins DA; Alam J; Chiang AY; Hu L; Krege JH; Sowa H; Mitlak BH; Myers SL
    J Bone Miner Res; 2015 Feb; 30(2):216-24. PubMed ID: 25196993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Romosozumab for the treatment of osteoporosis.
    Bandeira L; Lewiecki EM; Bilezikian JP
    Expert Opin Biol Ther; 2017 Feb; 17(2):255-263. PubMed ID: 28064540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on romosozumab : a humanized monoclonal antibody to sclerostin.
    Costa AG; Bilezikian JP; Lewiecki EM
    Expert Opin Biol Ther; 2014 May; 14(5):697-707. PubMed ID: 24665957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)].
    Quemerais-Durieu MA; Kerlan V; Chabre O
    Ann Endocrinol (Paris); 2011 Oct; 72 Suppl 1():S15-22. PubMed ID: 22008272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monoclonal antibodies to sclerostin for the treatment of osteoporosis].
    Soen S
    Clin Calcium; 2013 Jun; 23(6):884-9. PubMed ID: 23719502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile of romosozumab and its potential in the management of osteoporosis.
    Lim SY; Bolster MB
    Drug Des Devel Ther; 2017; 11():1221-1231. PubMed ID: 28458516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis.
    Shah AD; Shoback D; Lewiecki EM
    Int J Womens Health; 2015; 7():565-80. PubMed ID: 26082665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerostin: a novel target for intervention in the treatment of osteoporosis.
    Lewiecki EM
    Discov Med; 2011 Oct; 12(65):263-73. PubMed ID: 22031665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial watch: Bone-building antibody outshines current treatments in osteoporosis trial.
    Harrison C
    Nat Rev Drug Discov; 2014 Apr; 13(4):248. PubMed ID: 24625823
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical utility of anti-sclerostin antibodies.
    McClung MR
    Bone; 2017 Mar; 96():3-7. PubMed ID: 28115281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.